Equities Analysts Offer Predictions for TRVI Q2 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities researchers at B. Riley lowered their Q2 2025 earnings per share estimates for Trevi Therapeutics in a research report issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.14). B. Riley has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics’ Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.17) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.01.

Several other research analysts have also issued reports on TRVI. Oppenheimer increased their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright restated a “buy” rating and issued a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Needham & Company LLC lowered their target price on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, D. Boral Capital restated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $6.47 on Friday. The stock has a fifty day moving average price of $4.60 and a two-hundred day moving average price of $3.75. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.39. The firm has a market capitalization of $497.32 million, a P/E ratio of -14.70 and a beta of 0.90.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 24.37% of the stock is owned by company insiders.

Hedge Funds Weigh In On Trevi Therapeutics

Several hedge funds have recently added to or reduced their stakes in TRVI. Summit Investment Advisors Inc. boosted its holdings in Trevi Therapeutics by 84.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after buying an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares during the last quarter. Raymond James Financial Inc. bought a new position in Trevi Therapeutics during the fourth quarter worth about $49,000. Squarepoint Ops LLC bought a new position in Trevi Therapeutics during the fourth quarter worth about $58,000. Finally, Intech Investment Management LLC bought a new position in Trevi Therapeutics during the third quarter worth about $63,000. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.